Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
nties include among others theefficacy of REOLYSIN(R) as a cancer treatment the success and timelycompletion of clinical studies and trials uncertainties related to theresearch and development of pharmaceuticals and uncertainties related tothe regulatory process. Investors should consult the Company's quarterlyand annual filings with the Canadian and U.S. securities commissions foradditi
Date:11/1/2007